18.207.132.226
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Retina

Gene therapy for choroideremia fails in late-stage clinical trial

The phase 3 STAR study investigating timrepigene emparvovec (BIIB111/AAV2-REP1; Biogen), an investigational gene therapy for the treatment of choroideremia, did not meet its primary endpoint of proportion of participants with a ≥15 letter improvement from baseline in best-corrected visual acuity (BCVA) at 12 months, according to a press release. Key...

Read More
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-